• Expanded field force to increase the breadth of IH prescribers 9,050 9,300 9,500 9,525 9,900 2,000 2,200 2,550 2,775 3,050 Narcolepsy IH 12,050 11,050 11,500 12,300 12,950 ACTIVE XYWAV PATIENTS1 1Q23 2Q23 3Q23 4Q23 1Q24 Sleep Franchise • Total 1Q24 sleep revenue of $430 2 million • Expect high-sodium AG royalty revenue to exceed $200M in 2024 Expect Xywav to Remain Oxybate of Choice • Revenue grew 14% YoY Narcolepsy • Benefits of reducing sodium intake and an individualized dosing regimen continue to reso ...

DUBLIN, May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Global Health Care Conference on Wednesday, May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.   An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of ...

[Financial & Operational Highlights](index=1&type=section&id=Key%20Highlights) Jazz Pharmaceuticals reported strong Q1 2024 results, with key growth drivers and oncology portfolio showing double-digit revenue growth, affirming full-year guidance Q1 2024 Key Growth Driver Performance (YoY) | Product | Net Product Sales Growth (YoY) % | | :--- | :--- | | Xywav | 14 | | Epidiolex/Epidyolex | 5 | | Rylaze | 20 | - The company completed the Biologics License Application (BLA) submission for zanidatamab, seeking accelerated approval for second-line biliary tract cancer (BTC)[4](index=4&type=chunk) - Multiple near-term, late-stage pipeline catalysts are anticipated, including top-line data for suvecaltamide in essential tremor (late 1H24) and zanidatamab in 1L gastroesophageal adenocarcinoma (late 2024)[4](index=4&type=chunk) - Full-year 2024 total revenue guidance was affirmed at **$4.0 to $4.2 billion**[1](index=1&type=chunk)[4](index=4&type=chunk) [Business and Pipeline Updates](index=2&type=section&id=Business%20Updates) Strong commercial performance, led by Xywav's 14% sales increase, complemented significant pipeline advancements including zanidatamab BLA submission and suvecaltamide trial enrollment completion [Key Commercial Products Performance](index=2&type=section&id=Key%20Commercial%20Products) Q1 2024 saw Xywav sales grow 14% to **$315.3 million**, Rylaze 20% to **$102.8 million**, and Zepzelca 12% to **$75.1 million**, while Xyrem declined due to patient transition Xywav Performance (Q1 2024) | Metric | Value | | :--- | :--- | | Net Product Sales | $315.3 million (+14% YoY) | | Total Active Patients | ~12,950 | | Narcolepsy Patients | ~9,900 | | Idiopathic Hypersomnia (IH) Patients | ~3,050 | Other Key Product Sales (Q1 2024) | Product | Net Sales | Change (YoY) % | | :--- | :--- | :--- | | Rylaze/Enrylaze | $102.8 million | +20 | | Zepzelca | $75.1 million | +12 | | Epidiolex/Epidyolex | $198.7 million | +5 | | Xyrem | $64.2 million | -64 | - Royalties from high-sodium oxybate authorized generics (AGs) were **$49.9 million** in Q1 2024, and are expected to exceed **$200 million** for the full year[10](index=10&type=chunk) [Key Pipeline Highlights](index=3&type=section&id=Key%20Pipeline%20Highlights) Pipeline advanced with zanidatamab BLA submission for 2L BTC and completed enrollment for suvecaltamide Phase 2b essential tremor trial, with key data readouts anticipated - Zanidatamab: The BLA for 2L BTC was submitted to the FDA. A pivotal trial in 1L gastroesophageal adenocarcinoma (GEA) is ongoing, with top-line PFS data targeted for late 2024[12](index=12&type=chunk)[14](index=14&type=chunk) - Suvecaltamide (JZP385): Enrollment for the Phase 2b trial in essential tremor (ET) was completed in Q1 2024, with top-line data anticipated in late 1H24[13](index=13&type=chunk)[14](index=14&type=chunk) - Zepzelca: Enrollment in the Phase 3 trial for 1L small cell lung cancer (SCLC) was completed in Q1 2024, with top-line PFS data expected at the end of 2024 or early 2025[11](index=11&type=chunk) [Financial Performance](index=3&type=section&id=Financial%20Highlights) Q1 2024 total revenues grew 1% to **$902.0 million**, but GAAP net loss of **$14.6 million** resulted from increased R&D and SG&A expenses, while non-GAAP adjusted net income was **$182.2 million** [Financial Highlights Summary](index=3&type=section&id=Financial%20Highlights%20Summary) Q1 2024 GAAP net loss was **$14.6 million** (**$(0.23)** per share), a decline from Q1 2023 net income, with non-GAAP adjusted net income at **$182.2 million** (**$2.68** per diluted share) Q1 2024 vs. Q1 2023 Financial Results | Metric (in thousands, except per share) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Total Revenues | $901,983 | $892,812 | | GAAP Net Income (Loss) | $(14,618) | $69,420 | | GAAP EPS (Loss) | $(0.23) | $1.04 | | Non-GAAP Adjusted Net Income | $182,215 | $285,261 | | Non-GAAP Adjusted EPS | $2.68 | $3.95 | [Total Revenues](index=4&type=section&id=Total%20Revenues) Q1 2024 total revenues increased 1% YoY to **$902.0 million**, driven by oncology sales and AG royalty revenue, partially offset by declining Neuroscience revenue due to Xyrem sales Revenue Breakdown (in thousands) | Revenue Source | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | **Neuroscience** | | | | Xywav | $315,300 | $277,761 | | Xyrem | $64,232 | $178,130 | | Epidiolex/Epidyolex | $198,716 | $188,909 | | **Total Neuroscience** | **$580,983** | **$651,898** | | **Oncology** | | | | Rylaze/Enrylaze | $102,750 | $85,927 | | Zepzelca | $75,100 | $67,181 | | **Total Oncology** | **$257,549** | **$228,887** | | High-sodium oxybate AG royalty revenue | $49,947 | $2,096 | | **Total Revenues** | **$901,983** | **$892,812** | [Operating Expenses](index=4&type=section&id=Operating%20Expenses%20and%20Effective%20Tax%20Rate) Q1 2024 GAAP SG&A and R&D expenses increased to 39.0% and 24.7% of revenues, driven by higher compensation, program investments, and litigation costs GAAP Operating Expenses as % of Total Revenues | Expense Category | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Gross Margin | 88.7% | 85.5% | | SG&A | 39.0% | 33.4% | | R&D | 24.7% | 21.2% | - Increases in SG&A and R&D expenses were primarily driven by higher compensation-related costs due to increased headcount, investment in priority programs like zanidatamab, and litigation costs[20](index=20&type=chunk) [Cash Flow and Balance Sheet](index=5&type=section&id=Cash%20Flow%20and%20Balance%20Sheet) As of March 31, 2024, the company held **$1.8 billion** in cash and investments, with **$5.8 billion** in long-term debt, and generated **$267.2 million** in cash from operations Key Balance Sheet and Cash Flow Items (as of March 31, 2024) | Item | Value | | :--- | :--- | | Cash, cash equivalents and investments | $1.8 billion | | Principal balance of long-term debt | $5.8 billion | | Cash from operations (for Q1 2024) | $267.2 million | [2024 Financial Guidance](index=6&type=section&id=2024%20Financial%20Guidance) Jazz Pharmaceuticals affirmed full-year 2024 guidance, projecting total revenues of **$4.0-$4.2 billion** and non-GAAP adjusted diluted EPS of **$18.15-$19.35** Full Year 2024 Revenue Guidance (in millions) | Segment | Guidance | | :--- | :--- | | Total Revenues | $4,000 - $4,200 | | Neuroscience | $2,800 - $2,950 | | Oncology | $1,120 - $1,220 | Full Year 2024 Profitability Guidance | Metric | GAAP | Non-GAAP Adjusted | | :--- | :--- | :--- | | Net Income (in millions) | $385 - $530 | $1,275 - $1,350 | | Net Income per Diluted Share | $5.80 - $7.70 | $18.15 - $19.35 | [Consolidated Financial Statements](index=10&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20INCOME%20%28LOSS%29) This section presents unaudited condensed consolidated financial statements for Q1 2024, including income statement with **$14.6 million** net loss, balance sheet with **$11.3 billion** total assets, and cash flow statement with **$267.2 million** cash from operations [Condensed Consolidated Statements of Income (Loss)](index=10&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20INCOME%20%28LOSS%29) For Q1 2024, total revenues were **$902.0 million**, resulting in a net loss of **$14.6 million**, or **$(0.23)** per diluted share, after **$835.8 million** in operating expenses Q1 2024 Income Statement Summary (in thousands) | Line Item | Three Months Ended March 31, 2024 | | :--- | :--- | | Total revenues | $901,983 | | Total operating expenses | $835,776 | | Income from operations | $66,207 | | Net income (loss) | $(14,618) | | Diluted net income (loss) per share | $(0.23) | [Condensed Consolidated Balance Sheets](index=11&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of March 31, 2024, total assets were **$11.33 billion**, total liabilities **$7.63 billion**, and total shareholders' equity **$3.70 billion**, with cash and cash equivalents at **$1.44 billion** Balance Sheet Summary (in thousands) | Line Item | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $1,443,385 | $1,506,310 | | Total current assets | $3,539,898 | $3,435,428 | | Total assets | $11,327,075 | $11,393,359 | | Total current liabilities | $1,562,206 | $1,536,692 | | Total liabilities | $7,630,614 | $7,656,362 | | Total shareholders' equity | $3,696,461 | $3,736,997 | [Summary of Cash Flows](index=11&type=section&id=SUMMARY%20OF%20CASH%20FLOWS) For Q1 2024, net cash from operations was **$267.2 million**, while investing activities used **$271.9 million** and financing activities used **$56.6 million**, leading to a **$62.9 million** net decrease in cash Cash Flow Summary (in thousands) | Line Item | Three Months Ended March 31, 2024 | | :--- | :--- | | Net cash provided by operating activities | $267,229 | | Net cash used in investing activities | $(271,904) | | Net cash used in financing activities | $(56,552) | | Net decrease in cash and cash equivalents | $(62,925) | [Reconciliation of GAAP to Non-GAAP Measures](index=12&type=section&id=RECONCILIATIONS%20OF%20GAAP%20REPORTED%20TO%20NON-GAAP%20ADJUSTED%20INFORMATION) This section details GAAP to non-GAAP reconciliations, showing Q1 2024 GAAP net loss of **$14.6 million** adjusted to **$182.2 million** non-GAAP net income, with similar adjustments for full-year guidance Reconciliation of Q1 2024 GAAP Net Loss to Non-GAAP Adjusted Net Income (in thousands) | Description | Amount | | :--- | :--- | | **GAAP reported net loss** | **$(14,618)** | | Intangible asset amortization | $155,730 | | Share-based compensation expense | $61,441 | | Acquisition accounting inventory fair value step-up | $28,943 | | Non-cash interest expense | $4,846 | | Income tax effect of above adjustments | $(54,127) | | **Non-GAAP adjusted net income** | **$182,215** | Reconciliation of 2024 GAAP to Non-GAAP Diluted EPS Guidance | Description | Diluted EPS Range | | :--- | :--- | | **GAAP guidance** | **$5.80 - $7.70** | | Intangible asset amortization | $8.55 - $9.15 | | Acquisition accounting inventory fair value step-up | $1.75 - $2.05 | | Share-based compensation expense | $3.80 - $4.25 | | Non-cash interest expense | $0.30 - $0.40 | | Income tax effect of above adjustments | $(2.90) - $(3.20) | | **Non-GAAP guidance** | **$18.15 - $19.35** |

Wall Street expects a year-over-year increase in earnings on higher revenues when Jazz Pharmaceuticals (JAZZ) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May ...

Two oral presentations share results of real-world impact of idiopathic hypersomnia and long-term effectiveness of Epidiolex® (cannabidiol) in treatment-resistant epilepsies Thirteen abstracts underscore Jazz's diverse neuroscience portfolio and pioneering efforts to continue advancing the treatment of serious sleep disorders, rare epilepsy syndromes and movement disorders DUBLIN, April 10, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts from across its neurosc ...

Submission based on data from Phase 2b HERIZON-BTC-01 trial, which met its primary endpoint in patients receiving zanidatamab for previously treated HER2-positive biliary tract cancer (BTC) Confirmatory Phase 3 trial in first-line (1L) BTC open for enrollment at multiple global sites DUBLIN, April 2, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administrat ...

DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m. ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers. The webcast will highlight the mechanistic rationale and clinical data that support further development of zanidatamab as a treatment for biliary tract cancer (BTC), gastroesop ...

Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $5.02 per share in fourth-quarter 2023, missing the Zacks Consensus Estimate of $5.26. In the year-ago period, the company reported an adjusted loss of 7 cents per share.Total revenues in the reported quarter rose 4% year over year to $1.01 billion. Sales of Xywav, Epidiolex and Rylaze drove the upside. Total revenues were in line with the Zacks Consensus Estimate. Per management, this was the first time where the company achieved a billion dollars i ...

For the quarter ended December 2023, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.01 billion, up 4.1% over the same period last year. EPS came in at $5.02, compared to -$0.07 in the year-ago quarter.The reported revenue represents a surprise of +0.37% over the Zacks Consensus Estimate of $1.01 billion. With the consensus EPS estimate being $5.26, the EPS surprise was -4.56%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to dete ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.02 per share, missing the Zacks Consensus Estimate of $5.26 per share. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.56%. A quarter ago, it was expected that this drugmaker would post earnings of $4.90 per share when it actually produced earnings of $4.84, delivering a surprise of -1.22%.Over the last four quarters, the compa ...